Pharsight

Bristol Myers Squibb Co patents expiration

1. Abraxane patents expiration

ABRAXANE's oppositions filed in EPO
ABRAXANE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8314156 BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Dec, 2023

(2 months from now)

US8138229 BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Dec, 2023

(2 months from now)

US7923536 BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Dec, 2023

(2 months from now)

US8138229

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(8 months from now)

US7923536

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(8 months from now)

US8314156

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(8 months from now)

US7820788 BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Oct, 2024

(1 year, 29 days from now)

US7820788

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Apr, 2025

(1 year, 6 months from now)

US9101543 BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(2 years from now)

US8268348 BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(2 years from now)

US7758891 BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(2 years from now)

US8034375 BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

US9101543

(Pediatric)

BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

US7758891

(Pediatric)

BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

US8268348

(Pediatric)

BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

US8034375

(Pediatric)

BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2027

(3 years from now)

US9597409 BRISTOL MYERS SQUIBB CO Methods of treating cancer
Mar, 2032

(8 years from now)

US9393318 BRISTOL MYERS SQUIBB CO Methods of treating cancer
Mar, 2032

(8 years from now)

US9597409

(Pediatric)

BRISTOL MYERS SQUIBB CO Methods of treating cancer
Sep, 2032

(8 years from now)

US9393318

(Pediatric)

BRISTOL MYERS SQUIBB CO Methods of treating cancer
Sep, 2032

(8 years from now)

US9511046 BRISTOL MYERS SQUIBB CO Methods of treating pancreatic cancer
Jan, 2034

(10 years from now)

US9511046

(Pediatric)

BRISTOL MYERS SQUIBB CO Methods of treating pancreatic cancer
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer; Treatment of pancreatic cancer; Treatment of breast cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic